COLLEGIUM PHARMACEUTICAL INC (COLL)
US19459J1043 - Common Stock
Collegium to Participate in Upcoming Investor Conferences
Collegium Reports Record Third Quarter 2024 Financial Results
Collegium Reports Record Third Quarter 2024 Financial Results
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER...
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses...
Collegium Pharmaceutical is Now Oversold (COLL)
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
Collegium Pharmaceutical (COLL) Shares Cross Below 200 DMA
Collegium Completes Acquisition of Ironshore Therapeutics
Collegium Completes Acquisition of Ironshore Therapeutics
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect...
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Collegium Pharmaceutical (NASDAQ:COLL) just reported results for the second qua...
Collegium Reports Second Quarter 2024 Financial Results
Collegium Reports Second Quarter 2024 Financial Results
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – –...
First Week of March 2025 Options Trading For Collegium Pharmaceutical (COLL)
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32%...
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Collegium to Participate in Jefferies Global Healthcare Conference
Collegium to Participate in Jefferies Global Healthcare Conference
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company...
Collegium Announces $35 Million Accelerated Share Repurchase Program
Collegium Announces $35 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company...